{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:27:53Z","timestamp":1794302873077,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.08.043","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:05:42Z","timestamp":1788221142000},"page":"383-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Voretigene Neparvovec (Luxturna) for Biallelic RPE65\u2013Associated Retinal Dystrophy: Systematic Review"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2923-2835","authenticated-orcid":false,"given":"ABU BAKAR","family":"BUTT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHELE","family":"ZAMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREW","family":"MIHALACHE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SARA","family":"KAMALIZONOUZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PARSA BABAEI","family":"ZADEH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6341-4473","authenticated-orcid":false,"given":"YAKSH R.","family":"SHAH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARKO M.","family":"POPOVIC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETER J.","family":"KERTES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRIAN G.","family":"BALLIOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AJOY","family":"VINCENT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ELISE","family":"HEON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAJEEV H.","family":"MUNI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RADHA P.","family":"KOHLY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ajo.2026.08.043_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113467","article-title":"Inherited retinal diseases","volume":"23","author":"Ben-Yosef","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.043_bib0002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: progress and possibilities","volume":"104","author":"Hu","year":"2021","journal-title":"Clin Exp Optom"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.043_bib0003","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14712598.2020.1740676","article-title":"Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development","volume":"20","author":"Ciulla","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ajo.2026.08.043_bib0004","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2147\/OPTH.S231804","article-title":"Voretigene neparvovec in retinal diseases: a review of the current clinical evidence","volume":"14","author":"Gao","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.08.043_bib0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation\u2013associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"10097","key":"10.1016\/j.ajo.2026.08.043_bib0006","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.043_bib0007","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ophtha.2019.12.003","article-title":"The evolution of retinal gene therapy: from clinical trials to clinical practice","volume":"127","author":"Pennesi","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.043_bib0008","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.08.043_bib0009","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2026.08.043_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jclinepi.2023.06.015","article-title":"Risk-of-bias assessment using Cochrane\u2019s revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review","volume":"161","author":"Crocker","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.043_bib0011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.043_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation\u2013associated inherited retinal degeneration in a clinical setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.043_bib0013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajo.2026.08.043_bib0014","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.oret.2024.01.021","article-title":"Objective outcomes to evaluate voretigene neparvovec treatment effects in clinical practice","volume":"8","author":"Melillo","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"10.1016\/j.ajo.2026.08.043_bib0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","article-title":"Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy","volume":"37","author":"Jalil","year":"2023","journal-title":"Eye (Lond)"},{"issue":"9","key":"10.1016\/j.ajo.2026.08.043_bib0016","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.043_bib0017","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.043_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101484","article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.043_bib0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00417-023-06237-4","article-title":"Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics","volume":"262","author":"Jung","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.043_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.043_bib0021","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/IAE.0000000000003576","article-title":"Retinal pigment epithelium atrophy after subretinal voretigene neparvovec-rzyl for RPE65-related disease: a 6-month follow-up","volume":"42","author":"Giansanti","year":"2022","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ajo.2026.08.043_bib0022","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","article-title":"Inflammation after voretigene neparvovec administration in patients with RPE65-related retinal dystrophy","volume":"129","author":"Kessel","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.043_bib0023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/13816810.2022.2053995","article-title":"The first gene therapy for RPE65 biallelic dystrophy with voretigene neparvovec-rzyl in Brazil","volume":"43","author":"Ferraz Sallum","year":"2022","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.043_bib0024","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","article-title":"Visual acuity, retinal morphology, and patients\u2019 perceptions after voretigene neparvovec-rzyl therapy for RPE65-associated retinal disease","volume":"6","author":"Sengillo","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.043_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2020-318286","article-title":"Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec","volume":"106","author":"Stingl","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.043_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22180-6","article-title":"Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy","volume":"12","author":"Testa","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.043_bib0027","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1111\/aos.14990","article-title":"Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec","volume":"100","author":"Kort\u00fcm","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"10045","key":"10.1016\/j.ajo.2026.08.043_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.043_bib0029","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/j.jcjo.2024.12.013","article-title":"\"Blindness\" is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases","volume":"60","author":"Parameswarappa","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.043_bib0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bjo-2024-326221","article-title":"12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy","volume":"109","author":"Daruich","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.043_bib0031","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcjo.2024.12.006","article-title":"Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated leber congenital amaurosis","volume":"60","author":"Tayyib","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.043_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.13.6.11","article-title":"Perimacular atrophy following voretigene neparvovec-rzyl treatment in the setting of previous contralateral eye treatment with a different viral vector","volume":"13","author":"Ku","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.043_bib0033","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/s41433-025-03637-0","article-title":"Real-world Outcomes of voretigene neparvovec: a single-centre consecutive case series","volume":"39","author":"Jalil","year":"2025","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.043_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100876","article-title":"Efficacy and safety of voretigene neparvovec in RPE65-retinopathy: results of a phase III trial in Japan","volume":"5","author":"Fujinami","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.043_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10633-024-09987-6","article-title":"Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl","volume":"149","author":"Amato","year":"2024","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.ajo.2026.08.043_bib0036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.exer.2015.02.017","article-title":"Structure and function of the interphotoreceptor matrix surrounding retinal photoreceptor cells","volume":"133","author":"Ishikawa","year":"2015","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.043_bib0037","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","article-title":"Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy","volume":"29","author":"Cideciyan","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.08.043_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations","volume":"86","author":"Botto","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.043_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031138","article-title":"Retinal plasticity","volume":"23","author":"Strettoi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajo.2026.08.043_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/568354","article-title":"Plasticity in the human visual cortex: an ophthalmology-based perspective","volume":"2013","author":"Rosa","year":"2013","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.043_bib0041","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11427-021-2030-6","article-title":"New treatment for amblyopia based on rules of synaptic plasticity: a randomized clinical trial","volume":"65","author":"Huang","year":"2022","journal-title":"Sci China Life Sci"},{"issue":"20","key":"10.1016\/j.ajo.2026.08.043_bib0042","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N Engl J Med"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:07:08Z","timestamp":1794301628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":42,"alternative-id":["S0002939426004988"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.043","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Voretigene Neparvovec (Luxturna) for Biallelic RPE65\u2013Associated Retinal Dystrophy: Systematic Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}